With over 24.03 million OncoSec Medical Incorporated (ONCS) shares trading Tuesday and a closing price of $3.85 on the day, the dollar volume was approximately $92.52 million. The shares have shown a negative half year performance of -79.23% and its price on 11/29/22 gained nearly 50.98%. Currently, there are 1.79M common shares owned by the public and among those 0.79M shares have been available to trade.
Insiders at the company have transacted a total of 3 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 3 occasions, with total insider shares sold totaling 967 shares.
Shares of OncoSec Medical Incorporated (NASDAQ: ONCS) opened at $3.56, up $1.01 from a prior closing price of $2.55. However, the script later moved the day high at 3.9700, up 50.98%. The company’s stock has a 5-day price change of -20.62% and -74.27% over the past three months. ONCS shares are trading -81.76% year to date (YTD), with the 12-month market performance down to -85.77% lower. It has a 12-month low price of $2.52 and touched a high of $34.76 over the same period. ONCS has an average intraday trading volume of 313.63K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -28.17%, -54.13%, and -76.03% respectively.
Institutional ownership of OncoSec Medical Incorporated (NASDAQ: ONCS) shares accounts for 13.90% of the company’s 1.79M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $7.24M and a beta (3y monthly) value of 1.60. The earnings-per-share (ttm) stands at -$19.14. Price movements for the stock have been influenced by the stock’s volatility, which stands at 33.92% over the week and 21.94% over the month.
Analysts forecast that OncoSec Medical Incorporated (ONCS) will achieve an EPS of -$0.24 for the current quarter, -$0.19 for the next quarter and -$0.66 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.24 while analysts give the company a high EPS estimate of -$0.24. Comparatively, EPS for the current quarter was -$0.29 a year ago. Earnings per share for the fiscal year are expected to increase by 36.70%, and 79.30% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate OncoSec Medical Incorporated (ONCS) as a “Hold” at a consensus score of 3.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 1 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ONCS, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on March 08, 2021, with the firm’s price target at $10. Dawson James coverage for the OncoSec Medical Incorporated (ONCS) stock in a research note released on July 27, 2020 offered a Buy rating with a price target of $10. H.C. Wainwright was of a view on November 07, 2018 that the stock is Neutral, while Piper Jaffray gave the stock Overweight rating on February 09, 2018, issuing a price target of $4. Rodman & Renshaw on their part issued Buy rating on July 21, 2016.